Abstract:
This dissertation explores potential therapeutic targets for NUT carcinoma (NC), a rare and
aggressive cancer with few treatment options, by examining its tumor microenvironment (TME)
through immunohistochemistry, and advanced multiplex imaging, using the MACSima system.
A customized immuno-oncology antibody panel is established and applied to analyze the TME
of NCs in detail and explore potential therapeutic targets. The study additionally compares
long-term and short-term survivors (cut-off value 6 months) to identify prognostic markers. Key
findings of this study reveal that NCs exhibited significantly greater immune infiltration than
previously anticipated, challenging the prior understanding that NCs are "cold tumors" with
limited immune involvement. These results provide important new insights into TME of NCs, a
subject with little prior knowledge. Immune profiling of the TME show notable differences
between survivor groups, with short-term survivors exhibiting higher levels of granulocytes, M2
macrophages, and exhausted T-cells, as well as an increased intratumoral lymphocyte-togranulocyte ratio. With few established prognostic factors especially regarding the TME, the
prognostic factors identified in this study, including immune cell profiles and their relation to
survival outcomes, can help pinpoint high-risk patients, enabling more effective therapeutic
stratification and personalized treatment approaches for patients with NC. Additionally, this
study reveals that the examined NCs predominantly expressed CD276 and EGFR, identifying
these molecules as promising targets for therapeutic intervention that could potentially prolong
survival through targeted immunotherapy.